CTL019 Clinical Pharmacology and Biopharmaceutics in Pediatric Patients with Relapsed or Refractory (R/R) Acute Lymphoblastic Leukemia (ALL)

CTL019 is an investigational therapy whereby autologous T cells are genetically engineered with a chimeric antigen receptor (CAR) to identify and eliminate CD19-expressing malignant B cells.

Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Karen Thudium Mueller, Edward Waldron, Stephan A. Grupp, John Levine, Theodore W. Laetsch, Michael A. Pulsipher, Michael Boyer, Keith August, Jason Hamilton, Rakesh Awasthi, Denise Sickert, Abhijit Chakraborty, Bruce L. Levine, Carl H. June, Lori Tomassia Source Type: research